Browse the evidence

Bariatric surgery is a highly effective therapeutic option for individuals with severe obesity (BMI ≥40 or ≥35 with comorbidities) that induces T2DM remission through metabolic changes beyond simple restriction.

If you have a BMI of 40 or higher (or 35+ with diabetes/liver disease), consult a specialist about bariatric surgery. It is a proven, durable treatment that can reverse diabetes through hormonal changes, not just weight loss, but requires lifelong medical monitoring.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) improve MASH resolution but do not significantly improve liver fibrosis in patients with compensated cirrhosis.

Semaglutide (2.4mg weekly) helps resolve MASH but does not reverse fibrosis in patients with cirrhosis. It is effective for weight loss and glucose control but should not be relied upon to fix advanced scarring alone.

Smoking and consumption of goitrogenic foods (specifically cruciferous vegetables and processed meats) increase urinary levels of thiocyanate and nitrate, which act as competitive inhibitors of iodine uptake, thereby increasing the risk of iodine deficiency.

Smokers and those eating large amounts of cruciferous vegetables (broccoli, cabbage) or processed meats may have higher levels of goitrogens (thiocyanate/nitrate) in their urine. These substances compete with iodine for absorption. If you smoke or eat these foods heavily, ensure your iodine intake is adequate through diet or supplements to counteract this inhibition.

Pharmacological activation of G protein-coupled receptors (GPCRs) in thermogenic brown and beige adipocytes can increase energy expenditure and improve metabolic health, but current adrenergic agonists have a narrow safety window due to cardiovascular side effects.

While cold exposure is a natural way to activate brown fat, scientists are developing drugs that target specific receptors (GPCRs) to do the same thing. Current drugs like mirabegron show promise for boosting metabolism by ~200 kcal/day, but they can affect heart rate. Future treatments aim to target these receptors more selectively to avoid side effects while still improving metabolic health.

Non-adrenergic Gs-coupled receptors (e.g., secretin, glucagon, adenosine) can stimulate brown adipose tissue thermogenesis independently of the sympathetic nervous system, offering a potential pathway to avoid cardiovascular side effects associated with adrenergic agonists.

Scientists are exploring hormones other than adrenaline (like secretin or glucagon) to activate fat-burning cells. These hormones can boost glucose uptake in brown fat by 57%, but they break down quickly. Future drugs may modify these hormones to last longer, potentially offering a way to boost metabolism without the heart risks of current adrenaline-targeting drugs.

Resmetirom, a selective thyroid hormone receptor beta (THR-β) agonist, significantly reduces hepatic fat content and improves fibrosis markers in patients with non-cirrhotic MASH.

If you have MASH (formerly NASH) with significant liver fat, ask your doctor about resmetirom. It is an FDA-approved medication that targets the liver specifically to reduce fat and improve fibrosis. The standard dose is 80mg or 100mg taken once daily. It is not a supplement but a prescription drug with specific eligibility criteria (non-cirrhotic MASH).

Postprandial plasma leucine concentration and ingested leucine dose are poor predictors of muscle protein synthesis (MPS) rates when protein is consumed as whole foods or mixed meals, indicating that leucine is not the sole or primary driver of the anabolic response in complex nutritional contexts.

Stop obsessing over hitting specific leucine targets with isolated powders. When you eat whole protein sources like eggs, meat, or dairy, your body handles the anabolic signaling effectively regardless of minor variations in leucine content. The food matrix and other nutrients play a crucial role that isolated leucine metrics miss.

GLP-1 receptor agonists provide cardiovascular protection through peripheral anti-inflammatory effects, independent of their weight-loss or glucose-lowering actions.

Beyond helping you lose weight, GLP-1 medications like semaglutide have been shown to protect your heart. This protection comes from reducing inflammation in your body's peripheral tissues, offering a dual benefit for metabolic and cardiovascular health.

Pegozafermin (BIO89-100), an FGF-21 analog, demonstrates improvement in liver fibrosis in patients with MASH, as shown in Phase 2b trials, and has entered Phase 3 clinical trials.

Pegozafermin is an experimental drug for MASH that works by mimicking FGF-21. It is given as a subcutaneous injection every two weeks. It is currently in Phase 3 trials and not yet approved.

Pioglitazone, a PPAR-gamma agonist, improves steatosis, inflammation, and liver biomarkers in patients with MAFLD, but its effect on liver fibrosis is not clear.

Pioglitazone is an older diabetes drug that can improve liver fat and inflammation in MAFLD patients. However, it may cause weight gain and other side effects, and its ability to reverse liver scarring is unclear. It is sometimes used in patients with T2DM and MASH.

Chronic administration of GIP receptor agonists (specifically GIP108) causes functional desensitization of the GIP receptor in pancreatic islets, reducing the efficacy of subsequent glucose-lowering challenges.

Long-term use of GIP-based therapies (like tirzepatide) triggers a biological adaptation where the pancreas becomes less responsive to the drug's glucose-lowering signal. This is a known mechanism called desensitization. However, the drug still promotes weight loss, suggesting the benefit comes from multiple pathways, not just pancreatic sensitivity. If glycemic control wanes, dose adjustments may be necessary.

When adipose tissue storage capacity is exceeded, lipids are redirected to the pancreas causing lipotoxicity, beta-cell dysfunction, and type 2 diabetes.

If you have obesity but do not have diabetes, your body may still be successfully storing fat in your adipose tissue. If you have obesity and diabetes, your body may have reached its limit for storing fat safely, causing fat to leak into your pancreas and damage insulin-producing cells. Focus on improving adipose tissue function rather than just weight loss.

Saturated fatty acids induce beta-cell apoptosis and dysfunction through ceramide accumulation and ER stress, whereas minimal levels of fatty acids are required for normal insulin secretion.

Your body needs some fatty acids to function properly, but too much, especially saturated fat, can poison your insulin-producing cells. This happens when your fat storage cells are full, forcing fat into your pancreas. Managing saturated fat intake and supporting fat storage health are key.

Prolonged use of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for 3 years or more can enhance beta-cell function.

For those who cannot or will not undergo surgery or strict dieting, long-term GLP-1 agonist therapy (3+ years) may help preserve your pancreas's insulin-producing capacity. This is a disease-modifying effect, not just glucose lowering.

GLP-1 receptor agonists increase perioperative aspiration risk due to delayed gastric emptying, requiring specific holding protocols before elective surgery.

If you are having elective surgery while taking GLP-1 medications, tell your surgeon and anesthesiologist. You may need to hold your medication before surgery to reduce the risk of aspiration. Follow the specific holding instructions provided by your medical team.

SGLT2 inhibitors reduce blood pressure and cardiovascular risk, potentially through central sympatho-inhibition, but do not necessarily reduce muscle sympathetic nerve activity (MSNA) in humans.

SGLT2 inhibitors (like Jardiance or Farxiga) lower blood sugar and protect the heart. While they work by removing glucose through urine, they may also have subtle effects on brain pathways that help lower blood pressure.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) significantly improves hepatic steatosis and increases the likelihood of MASH resolution without worsening fibrosis in patients with non-cirrhotic MASH.

If you have MASH without cirrhosis, ask your doctor about tirzepatide. Clinical trials show that weekly injections of 5-15mg can significantly resolve MASH and improve liver fat without worsening fibrosis. This is a promising option for managing liver health in addition to blood sugar and weight.

Resmetirom is approved for adults with non-cirrhotic MASH and advanced liver fibrosis (stage ≥ 2) and has shown histological efficacy in addressing steatohepatitis and fibrosis.

If you have MASH with advanced fibrosis but no cirrhosis, ask your doctor about resmetirom. It is an approved treatment that has been shown to improve both steatohepatitis and fibrosis with a favorable safety profile.

GLP-1 RAs improve histological markers of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and reduce liver fat in patients with MASLD, MetALD, and ALD.

If you have fatty liver disease (MASLD/MASH), GLP-1 medications like Semaglutide or Liraglutide can significantly improve liver inflammation and fat content, often leading to MASH resolution. This is especially beneficial if you also have obesity or Type 2 Diabetes. Discuss these options with your hepatologist, noting that while they improve liver histology, they may not always reverse advanced fibrosis.

GLP-1 receptor agonist therapy causes a significant increase in resting heart rate (RHR) during the initial 12 weeks of treatment, which is primarily mediated by a reduction in heart rate variability (HRV).

If you start a GLP-1 medication (like semaglutide or tirzepatide), expect your resting heart rate to increase by about 3 beats per minute over the first 3 months. This is a normal, mediated response involving your autonomic nervous system (HRV), not necessarily a sign of heart damage. If you use a wearable, track this trend, but consult your doctor if the increase is extreme or accompanied by other symptoms.

SGLT2 inhibitors improve vascular function by reducing arterial stiffness, improving endothelial function (flow-mediated dilation), and reducing inflammation and oxidative stress.

These drugs don't just lower sugar; they physically improve the health of your blood vessels by making them more flexible and reducing the chemical stress (inflammation/oxidative stress) that damages them over time.

Peripheral GLP-1 receptor agonists (GLP-1RAs) exert brain-mediated anorectic effects primarily via access to circumventricular organs (CVOs) like the area postrema and median eminence, rather than crossing the blood-brain barrier (BBB) or blood-cerebrospinal fluid barrier (BCB).

GLP-1 medications like Semaglutide and Liraglutide reduce appetite by signaling from the gut to specific brain regions (CVOs) via the vagus nerve, rather than crossing into the brain tissue itself. This explains why they are effective for weight loss even though very little drug actually enters the cerebrospinal fluid.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) cause dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) primarily during dose escalation, leading to discontinuation in 3-17% of non-diabetic users.

If you are using a GLP-1 medication like semaglutide or tirzepatide, expect gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These symptoms are common but usually mild and transient. To manage them, follow a slow titration schedule, eat smaller, low-fat meals, and stay hydrated. Most people adapt over time, but if side effects are severe, consult your doctor about adjusting the dose.

Intermittent Hypoxia (IH) is a key pathogenic factor in OSA that drives cardiovascular and metabolic disease through vascular remodelling, atherosclerosis, and insulin resistance, independent of obesity.

The repeated drops in oxygen during sleep (Intermittent Hypoxia) are what actually damage your heart and metabolism, not just the breathing stops themselves. Managing OSA is crucial to prevent this cycle of damage.